VEGFC and neoplasm: Studies on mechanisms of tumour resistance indicate that resistance to aflibercept coincides with increased levels of VEGF-C [153], a lymphangiogenic growth factor [154] and that resistance to bevacizumab coincides with increased levels of PlGF and VEGF-D [155].